Results for tag: "Gemcabene"

Gemcabene is a novel cardiovascular drug developed by Acasti Pharma Inc. It is a prescription omega-3 fatty acid-based drug that is used to reduce triglyceride levels in adults with severe hypertriglyceridemia. Gemcabene is the first and only omega-3 fatty acid-based drug approved by the U.S. Food and Drug Administration (FDA) for this indication. Gemcabene is a once-daily oral medication that works by inhibiting the synthesis of triglycerides in the liver. It is also believed to reduce inflammation and improve endothelial function. The Gemcabene market is a rapidly growing segment of the cardiovascular drug market. It is expected to benefit from the increasing prevalence of hypertriglyceridemia and the growing awareness of the importance of managing triglyceride levels. The market is also expected to benefit from the increasing availability of generic versions of Gemcabene. Some of the key players in the Gemcabene market include Acasti Pharma Inc., Amarin Corporation, AstraZeneca, GlaxoSmithKline, Merck & Co., and Pfizer. Show Less Read more